Adult asthma is treated using two types of pharmacotherapy: rescue therapy to treat acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting underlying pathophysiology (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort); most adult asthma patients receive multiple agents to treat their condition. Despite the availability of multiple well-established therapies, in the last couple of years the adult asthma treatment landscape has witnessed the approval and launch of additional agents, including salmeterol / fluticasone generics and novel biological drugs (e.g., Regeneron / Sanofi’s Dupixent, GSK’s Nucala). These events have added more treatment options and fueled competition in this market.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult asthma patients?
- How have newer biological therapies, such as AstraZeneca’s Fasenra, been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult asthma patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of adult asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
- United States
Real World data:
- Longitudinal patient-level claims data analysis
Key Drugs Covered
- Advair, Symbicort, Dulera, AirDuo, Breo, Dupixent, Fasenra, Nucala, Ventolin, ProAir, montelukast sodium, Flovent, Qvar, Spiriva
Key Analysis provided
- Brand/therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Asthma - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult Asthma (US)
Author(s): Shubhendu Ghosh, PhD
Shubhendu Ghosh, Ph.D., is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma.
Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his Ph.D. in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.